Cardiff Oncology reported strong Phase 2 trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer, showing improved response rates and progression-free survival without added toxicity. The company completed a successful End-of-Phase 2 FDA meeting, selecting the onvansertib dose and chemotherapy regimen for the upcoming Phase 3 trial, with more details expected mid-2026. Cardiff also strengthened its leadership team and presented promising preclinical data on combination therapies, positioning itself for key clinical and regulatory milestones ahead. Financially, the company had $46.1 million in cash as of March 31, 2026, supporting operations into early 2027.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
